ica-105665

ICA-105665 is a novel, orally available small molecule developed as an opener (agonist) of neuronal KCNQ (Kv7) potassium channels, specifically targeting subtypes such as Kv7.2/7.3 and Kv7.3/7.5[1][9]. By activating these channels, ICA-105665 enhances the M-type potassium current, which plays a critical role in regulating neuronal excitability and suppressing epileptiform activity[1][4]. The drug was primarily investigated for the treatment of epilepsy and neuropathic pain, with preclinical studies demonstrating broad-spectrum antiseizure activity and some efficacy in models of neuropathic pain[1][2]. Clinical trials showed that ICA-105665 could reduce photoparoxysmal EEG responses in patients with photosensitive epilepsy, providing evidence for central nervous system penetration and target engagement[4][7]. Despite promising early results and good tolerability at doses up to 400 mg in healthy volunteers[8], development was discontinued after Phase II trials for epilepsy and Phase I trials for pain due to lack of further advancement or strategic reasons by the developer Icagen[2].

Other names

ICA105665ICA-105665ICA 105665